KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Equity (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Return on Equity for 14 consecutive years, with 0.04% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 11.0% to 0.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.04% through Dec 2025, down 11.0% year-over-year, with the annual reading at 0.04% for FY2025, 11.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.04% at Supernus Pharmaceuticals, down from 0.02% in the prior quarter.
  • The five-year high for Return on Equity was 0.15% in Q1 2021, with the low at 0.04% in Q4 2025.
  • Average Return on Equity over 5 years is 0.05%, with a median of 0.06% recorded in 2024.
  • The sharpest move saw Return on Equity fell -11bps in 2021, then increased 8bps in 2025.
  • Over 5 years, Return on Equity stood at 0.07% in 2021, then grew by 6bps to 0.07% in 2022, then plummeted by -98bps to 0.0% in 2023, then surged by 5077bps to 0.07% in 2024, then plummeted by -150bps to 0.04% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.04%, 0.02%, and 0.06% for Q4 2025, Q3 2025, and Q2 2025 respectively.